Skip to main content

Tweets

Zheng et al. Celiac disease more common in SLE aOR 2.88 (95%CI 2.60 –3.31). More common in white females. Assoc higher hospitalization cost and increased LOS @RheumNow #ACR22 Abstr#1192 https://t.co/kdwLmpIxNN https://t.co/ZdQJQn3QIF
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Abs 1011 examined fracture incidence rates in AS patients over time in VA cohort - Rate of fractures in AS pts 2.1 per 1000 PY --> 22.8 (1999 --> 2021) vs Comparators 0.4 --> 8.3 - Post TNF era fracture rates increased AS > comparators @RheumNow #ACR22 https://t.co/eUxoTavHGV
Akhil Sood MD @AkhilSoodMD ( View Tweet )
3 years 8 months ago
Table by ⁦@CuoghiE⁩ on how long to wait off #teratogenic meds before trying to conceive: note 2 years fr leflunomide unless a cholestyramine washout is done #ReproductiveRheum #ACR22 @rheumnow https://t.co/l4hIBQ5XN5
TheDaoIndex @KDAO2011 ( View Tweet )
3 years 8 months ago
A future rheumatologist attending the #ACR22 Plenary session virtually to keep up with the latest information. ⁦@RheumNow⁩ https://t.co/ttYr4iwTB8
Jonathan Kay, MD @RheumKay ( View Tweet )
3 years 8 months ago
Barroso-García et al. ADA vs IFX vs TCZ in severe ocular Behcets with refractory cystoid macular edema. Remission 76% (ADA), 60% (IFX), 67% (TCZ). @RheumNow #ACR22 Abstr#1564 https://t.co/pRVgIdGAGS https://t.co/gOb5wQ9pHv
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Does Bimekizumab, anti-IL17F, work in PsA? #ACR22 @RheumNow Abstract #L02 💊Phase 3, randomized, placebo-controlled study 💉Biologic naive patients ✋ Week 52: 53-54% BKZ groups achieved ACR502 (v. 50% in TNFi) 📍benefits sustained to week 52 🛑No new safety signals

Catherine Sims, MD @DrCassySims ( View Tweet )

3 years 8 months ago
Phase 2 efficacy and safety of deucravaticinib (TYK2i) in mod-severe SLE. Met primary endpoint (SRI4) for 3mg and 6mg doses (but not 12mg). No signal for HZ but increased oral herpes. Bigger numbers will be helpful. @RheumNow #ACR22 #plenary #ACRBest https://t.co/SjW1OSQzdM
Julian Segan @JulianSegan ( View Tweet )
3 years 8 months ago
PJP occurs in pts w/ AAV who undergo treatment w/ CYC or RTX, but PJP PPX assoc'd w/ inc incidence of medication-related adverse events. Abs 1081 #ACR22 @RheumNow https://t.co/7vMgx7eMAP https://t.co/bhKPtJBMAO
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
DEUC showed statistically significant and sustained clinical efficacy in SRI(4) responses versus PBO and was well tolerated in SLE. Plenary Abs 1117 #ACR22 @RheumNow https://t.co/iHPiA8FCwO https://t.co/A0FQ7zwL64
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
#ACR22 Plenary II Abstr#1117 Phase 2 results +ve in #lupus! Patients (65% White) on Deucravacitinib, TYK2-i had more SRI-4 response rates vs PBO. PBO:34.4%; DEUC 3 mg BID:58.2%, DEUC 6 mg BID:49.5%, DEUC 12 mg QD:44.9%. No major safety, slight increase in oral herpes @RheumNow https://t.co/QIJfoeP4dg
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
3 years 8 months ago
From my colleague @aili_yoyo. Mimics of vasculitis picked up on imaging. "Isolated abdominal vasculitis" is a surprisingly common consult. Can be tricky sometimes. @RheumNow #ACR22 #mimics https://t.co/QfeaTHHzdA
Julian Segan @JulianSegan ( View Tweet )
3 years 8 months ago
Rheumatic Masqueraders: Mimics of Rheumatic Diseases Mimics of Vasculitis by - Demographics - Vascular Distribution -**Imaging - Labs - Clinical Presentation #ACR22 @RheumNow https://t.co/o0pZoiMqI2
Akhil Sood MD @AkhilSoodMD ( View Tweet )
3 years 8 months ago
×